ES2409033T3 - Régimen de tratamiento de zoledronate intravenoso para el tratamiento de enfermedades del metabolismo óseo - Google Patents
Régimen de tratamiento de zoledronate intravenoso para el tratamiento de enfermedades del metabolismo óseo Download PDFInfo
- Publication number
- ES2409033T3 ES2409033T3 ES01935167T ES01935167T ES2409033T3 ES 2409033 T3 ES2409033 T3 ES 2409033T3 ES 01935167 T ES01935167 T ES 01935167T ES 01935167 T ES01935167 T ES 01935167T ES 2409033 T3 ES2409033 T3 ES 2409033T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- imidazol
- hydroxyethane
- minutes
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 title claims abstract description 75
- 238000011282 treatment Methods 0.000 title claims abstract description 43
- 201000010099 disease Diseases 0.000 title claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 15
- 230000004097 bone metabolism Effects 0.000 title claims abstract description 10
- 229960004276 zoledronic acid Drugs 0.000 title description 47
- 238000001990 intravenous administration Methods 0.000 title description 10
- 238000011269 treatment regimen Methods 0.000 title description 2
- 238000001802 infusion Methods 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 230000000148 hypercalcaemia Effects 0.000 claims description 10
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 10
- 206010027452 Metastases to bone Diseases 0.000 claims description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000018083 Bone metabolism disease Diseases 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 3
- 230000005747 tumor angiogenesis Effects 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 2
- 229940122361 Bisphosphonate Drugs 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 150000004663 bisphosphonates Chemical class 0.000 description 16
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 229940046231 pamidronate Drugs 0.000 description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- -1 bisphosphonate compound Chemical class 0.000 description 4
- 239000007951 isotonicity adjuster Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000001582 osteoblastic effect Effects 0.000 description 3
- 230000001599 osteoclastic effect Effects 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- 229940038773 trisodium citrate Drugs 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000000121 hypercalcemic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 231100000279 safety data Toxicity 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- JKQKNOPRCFYWCF-UHFFFAOYSA-N (1-hydroxy-2-imidazol-1-yl-2-phosphonoethyl)phosphonic acid Chemical compound OP(=O)(O)C(O)C(P(O)(O)=O)N1C=CN=C1 JKQKNOPRCFYWCF-UHFFFAOYSA-N 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000123 anti-resoprtive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000011240 pooled analysis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- HRJXMHAOFRMRCR-UHFFFAOYSA-J tetrasodium 2-hydroxypropane-1,2,3-tricarboxylate hydroxide Chemical compound [OH-].[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRJXMHAOFRMRCR-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940002005 zometa Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0012209.3A GB0012209D0 (en) | 2000-05-19 | 2000-05-19 | Organic compounds |
| GB0012209 | 2000-05-19 | ||
| PCT/US2001/014886 WO2001089494A2 (en) | 2000-05-19 | 2001-05-09 | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2409033T3 true ES2409033T3 (es) | 2013-06-24 |
Family
ID=9891987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01935167T Expired - Lifetime ES2409033T3 (es) | 2000-05-19 | 2001-05-09 | Régimen de tratamiento de zoledronate intravenoso para el tratamiento de enfermedades del metabolismo óseo |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1286665B1 (https=) |
| JP (3) | JP2004501104A (https=) |
| CN (1) | CN100389772C (https=) |
| AU (2) | AU2001261283B2 (https=) |
| BR (1) | BR0110913A (https=) |
| CA (1) | CA2409930C (https=) |
| ES (1) | ES2409033T3 (https=) |
| GB (1) | GB0012209D0 (https=) |
| WO (1) | WO2001089494A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014724A1 (en) | 2001-05-09 | 2004-01-22 | Seaman John J. | Method of administering a bisphosphonate |
| ES2394211T3 (es) | 2000-06-20 | 2013-01-23 | Novartis Ag | Procedimiento de administración de bifosfonatos |
| KR20060058151A (ko) | 2002-05-10 | 2006-05-29 | 에프. 호프만-라 로슈 아게 | 골다공증 치료 및 예방용 비스포스폰산 |
| AU2003270196A1 (en) * | 2002-09-16 | 2004-04-30 | Kenneth W. Lyles | Method for preventing or reducing secondary fractures after hip fracture |
| ES2291749T5 (es) | 2002-12-20 | 2011-07-21 | F. Hoffmann-La Roche Ag | Formulación de altas dosis de ibandronato. |
| MY141763A (en) * | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
| NZ555316A (en) | 2004-12-09 | 2009-08-28 | Merck & Co Inc | Estrogen receptor modulators |
| EP1930414B1 (en) * | 2005-09-08 | 2012-07-18 | Medinet Co., Ltd. | Method for activation treatment of antigen-presenting cell |
| US20100310626A1 (en) * | 2008-01-24 | 2010-12-09 | Remedor Biomed Ltd. | Erythropoietin and fibronectin compositions for bone regeneration |
| CN105920023A (zh) | 2009-09-01 | 2016-09-07 | 杜克大学 | 双膦酸类组合物及其治疗心力衰竭的方法 |
| CN102000035B (zh) * | 2010-10-13 | 2012-07-25 | 江苏奥赛康药业股份有限公司 | 一种供注射用的唑来膦酸组合物及其制备方法 |
| CN104010647A (zh) | 2011-11-16 | 2014-08-27 | 杜克大学 | 用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法 |
| RU2519120C1 (ru) * | 2012-11-06 | 2014-06-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ профилактики скелетных осложнений у больных с литическими метастазами в плоские и смешанные кости |
| DE102014004512A1 (de) * | 2014-03-28 | 2015-10-01 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin | Anorganisch-organische Hybridverbindung |
| BE1021270B1 (nl) * | 2014-06-17 | 2015-10-14 | Neogen N.V. | Zoledronine oplossing |
| CN105213407B (zh) * | 2015-07-01 | 2018-01-02 | 南京大学 | 唑来膦酸用于制备治疗脂肪性肝病的药物的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014724A1 (en) | 2001-05-09 | 2004-01-22 | Seaman John J. | Method of administering a bisphosphonate |
-
2000
- 2000-05-19 GB GBGB0012209.3A patent/GB0012209D0/en not_active Ceased
-
2001
- 2001-05-09 ES ES01935167T patent/ES2409033T3/es not_active Expired - Lifetime
- 2001-05-09 AU AU2001261283A patent/AU2001261283B2/en not_active Expired
- 2001-05-09 EP EP01935167.5A patent/EP1286665B1/en not_active Revoked
- 2001-05-09 CA CA2409930A patent/CA2409930C/en not_active Expired - Fee Related
- 2001-05-09 CN CNB018097812A patent/CN100389772C/zh not_active Ceased
- 2001-05-09 JP JP2001585739A patent/JP2004501104A/ja not_active Withdrawn
- 2001-05-09 BR BR0110913-8A patent/BR0110913A/pt not_active Application Discontinuation
- 2001-05-09 AU AU6128301A patent/AU6128301A/xx active Pending
- 2001-05-09 WO PCT/US2001/014886 patent/WO2001089494A2/en not_active Ceased
-
2012
- 2012-03-09 JP JP2012053573A patent/JP2012162531A/ja not_active Withdrawn
-
2013
- 2013-04-17 JP JP2013086245A patent/JP2013151553A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB0012209D0 (en) | 2000-07-12 |
| WO2001089494A8 (en) | 2003-04-17 |
| JP2013151553A (ja) | 2013-08-08 |
| CN100389772C (zh) | 2008-05-28 |
| CA2409930C (en) | 2012-08-28 |
| CN1481247A (zh) | 2004-03-10 |
| BR0110913A (pt) | 2003-12-30 |
| AU2001261283B2 (en) | 2005-01-13 |
| CA2409930A1 (en) | 2001-11-29 |
| JP2012162531A (ja) | 2012-08-30 |
| JP2004501104A (ja) | 2004-01-15 |
| EP1286665A2 (en) | 2003-03-05 |
| AU6128301A (en) | 2001-12-03 |
| WO2001089494A3 (en) | 2002-05-23 |
| EP1286665B1 (en) | 2013-04-17 |
| WO2001089494A2 (en) | 2001-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2409033T3 (es) | Régimen de tratamiento de zoledronate intravenoso para el tratamiento de enfermedades del metabolismo óseo | |
| ES2287191T3 (es) | Uso de acido zoledronico para el tratamiento del dolor. | |
| RU2238736C2 (ru) | Фармацевтическая парентеральная композиция, содержащая бифосфонат | |
| RU2297229C2 (ru) | Фармацевтическое применение бисфосфонатов | |
| AU2001261283A1 (en) | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | |
| AU2002257802A1 (en) | Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer | |
| US8324189B2 (en) | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | |
| CA3006954C (en) | Stable dosage form of etidronate-cytarabine conjugate, and use thereof | |
| WO2018016999A1 (ru) | Препарат для лечения костных поражений, вызванных злокачественными новообразованиями |